论文部分内容阅读
摘要目的评价尚存一定肝功能的伴段性或亚段性门静脉瘤栓(s PVTT)的肝细胞肝癌(HCC)病人行经动脉化学栓塞术(TACE)的临床转归和安全性,并探讨TACE后行额外化疗灌注(TACE+CI)的疗效。方法自2003年1月—2012年12月共81例伴s PVTT的HCC病人Child-Pugh评分≤7并行TACE。其中31例行TACE+CI。评估其生存率(OS)和严重不良事件(SAE)。TACE+CI的疗效通过逆处理概率加权法(IPTW)调整后进行评估。结果TACE后的生存率(中位值,15.5个月)与天冬氨酸转氨酶[风险比(HR),1.011]、修正的巴
Abstract Objective To evaluate the clinical outcome and safety of transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) who still have a definite hepatic function or with segmental portal vein tumor thrombosis (s PVTT) After additional chemotherapy infusion (TACE + CI) curative effect. Methods From January 2003 to December 2012 a total of 81 cases of HCC patients with PVTT Child-Pugh score ≤ 7 parallel TACE. TACE + CI was performed in 31 of them. The survival rate (OS) and serious adverse events (SAEs) were assessed. The efficacy of TACE + CI was assessed by inverse probability of treatment (IPTW) adjustments. Results TACE after survival (median, 15.5 months) was associated with aspartate aminotransferase [hazard ratio (HR), 1.011], modified bar